The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | MDS updates from ASH 2019
David Steensma
• 7 Dec 2019
David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, shares his highlights in myelodysplastic syndromes (MDS) from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. These include the APR-246 (NCT03072043) and magrolimab (NCT03248479) trials, as well as studies of IDH inhibitors.
